jpt2024年價格表
德國JPT公司,全稱JPT Peptide Technologies GmbH,是一家位于德國柏林的生物技術公司,專注于多肽的生產以及基于多肽的服務和相關產品 。JPT公司的產品廣泛應用于免疫學、基因組學和藥物研究領域,尤其是在蛋白組學、新型疫苗和藥物開發(fā)方面提供支持 。
JPT公司在多肽制造方面擁有超過20年的專業(yè)知識,并開發(fā)了專li技術,特別是在多肽庫、池和微陣列以及微尺度合成領域 。公司提供的服務范圍從微米級合成(10 - 50 nmol)到中間多肽合成(1 - 100 mg),每月能夠處理數(shù)萬個多肽的合成。此外,JPT允許客戶選擇肽的形式(如池、文庫、微陣列等)、肽的純度(從粗制到>98%)以及可選的修飾(如磷酸化、生物素標記、染料和標記、環(huán)化、偶聯(lián)、穩(wěn)定同位素標記等) 。
特別告知:為保證產品質量與良好性能,所以在購買相應產品的同時我司會收取一定量的運輸費用?。?!本次報價有效時間為2024年7月5日---2024年12月20日。
貨號 | 品名 | 規(guī)格 | 價格 | 品牌 | 貨期 | 價格來源 |
PM-VZV-gE | PepMix™ VZV (gE) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11118 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFX-2 | CEFX Ultra SuperStim Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 12971 | jpt | 4-6周 | 上海起發(fā) |
PM-HPV16-E7 | PepMix™ HPV 16 (E7) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-HBV-LEPULTRA | PepMix™ HBV (LEP) Ultra | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 13566 | jpt | 4-6周 | 上海起發(fā) |
PM-HPV16-E6 | PepMix™ HPV 16 (E6) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-HRSVB-FGF0 | PepMix™ HRSVB (Fusion Glycoprotein F0) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-E-3 | CEF Pool (extended) | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 4471 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFX-4 | CEFX Ultra SuperStim Pool MHC-I Subset | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 5355 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-LMP2 | PepMix™ EBV (LMP2) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 13464 | jpt | 4-6周 | 上海起發(fā) |
PM-HBV-CPULTRA | PepMix™ HBV (Capsid Protein) Ultra | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 14569 | jpt | 4-6周 | 上海起發(fā) |
PM-HRSVA-FGF0 | PepMix™ HRSVA (Fusion Glycoprotein F0) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-WCPV-S-1 | PepMix™ SARS-CoV-2 (Spike Glycoprotein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 17901 | jpt | 4-6周 | 上海起發(fā) |
PM-WCPV-S-RBD-1 | PepMix™ SARS-CoV-2 (S-RBD) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 8517 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-S-3 | CEF Pool (standard) | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 3893 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-MHC-II-1 | CEFT MHC-II Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 2890 | jpt | 4-6周 | 上海起發(fā) |
PM-IE1 | PepMix™ Human CMV (IE-1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9775 | jpt | 4-6周 | 上海起發(fā) |
PM-MOG | PepMix™ Human (MOG) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-MYCTU-AG85B | PepMix™ M. tuberculosis (Ag85B) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-OIP4 | PepMix™ Human (Prame/OIP4) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9775 | jpt | 4-6周 | 上海起發(fā) |
PM-PP65-1 | PepMix™ Human CMV (pp65) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-PP65-2 | PepMix™ Human CMV (pp65) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11118 | jpt | 4-6周 | 上海起發(fā) |
PM-WCPV-S-2 | PepMix™ SARS-CoV-2 (Spike Glycoprotein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 25058 | jpt | 4-6周 | 上海起發(fā) |
SP-MHCI-0001-1 | Antigen Peptide NY-ESO-1 - HLA-A*0201 (SLLMWITQC) | 50ug | 1904 | jpt | 4-6周 | 上海起發(fā) |
SP-MHCI-0006-1 | Antigen Peptide MART-1 (Leu27) - HLA-A*0201 (ELAGIGILTV) | 50ug | 1904 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-3 | CEFT Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 3893 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-4 | CEFT Pool | 120nmol/peptide | 23375 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFX-1 | CEFX Ultra SuperStim Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 10812 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-BMLF1 | PepMix™ EBV (BMLF1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-BMRF1 | PepMix™ EBV (BMRF1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-BRLF1 | PepMix™ EBV (BRLF1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-BZLF1 | PepMix™ EBV (BZLF1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-GP350/GP340 | PepMix™ EBV (GP350/GP340) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 14518 | jpt | 4-6周 | 上海起發(fā) |
PM-EBV-LMP1 | PepMix™ EBV (LMP1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 12512 | jpt | 4-6周 | 上海起發(fā) |
PM-HPV18-E6 | PepMix™ HPV 18 (E6) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-HPV18-E7 | PepMix™ HPV 18 (E7) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-HRSVA-MSG | PepMix™ HRSVA (Major Surface Glycoprotein G) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-HSV2-gD | PepMix™ HSV2 (gD) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-IE2 | PepMix™ Human CMV (IE-2) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-MAGEA4 | PepMix™ Human (MAGEA4) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-MYCTU-CFP10 | PepMix™ M. tuberculosis (CFP-10) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
EMPS-229E-S-1 | Epitope Mapping Peptide Set (EMPS) HCoV-229E (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-CVHSA-S-1 | Epitope Mapping Peptide Set (EMPS) SARS-CoV (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-HKU1-S-1 | Epitope Mapping Peptide Set (EMPS) HCoV-HKU1 (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-MERS-CoV-S-1 | Epitope Mapping Peptide Set (EMPS) MERS-CoV (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-NL63-S-1 | Epitope Mapping Peptide Set (EMPS) HCoV-NL63 (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-OC43-S-1 | Epitope Mapping Peptide Set (EMPS) HCoV-OC43 (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-WCPV-NCAP-1 | Epitope Mapping Peptide Set (EMPS) SARS-CoV-2 (NCAP) | 5ug/peptideasindividualpeptideandinmatrixpools | 65705 | jpt | 4-6周 | 上海起發(fā) |
EMPS-WCPV-S-1 | Epitope Mapping Peptide Set (EMPS) SARS-CoV-2 (Spike Glycoprotein) | 5ug/peptideasindividualpeptideandinmatrixpools | 96492 | jpt | 4-6周 | 上海起發(fā) |
EMPS-WCPV-VEMP-1 | Epitope Mapping Peptide Set (EMPS) SARS-CoV-2 (VEMP) | 5ug/peptideasindividualpeptideandinmatrixpools | 15708 | jpt | 4-6周 | 上海起發(fā) |
EMPS-WCPV-VME-1 | Epitope Mapping Peptide Set (EMPS) SARS-CoV-2 (VME1) | 5ug/peptideasindividualpeptideandinmatrixpools | 39491 | jpt | 4-6周 | 上海起發(fā) |
PM-229E-NCAP-1 | PepMix™ HCoV-229E (NCAP) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 8517 | jpt | 4-6周 | 上海起發(fā) |
PM-229E-S-1 | PepMix™ HCoV-229E (Spike Glycoprotein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 17901 | jpt | 4-6周 | 上海起發(fā) |
PM-229E-S-2 | PepMix™ HCoV-229E (Spike Glycoprotein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 25058 | jpt | 4-6周 | 上海起發(fā) |
PM-AAV2-VP1 | PepMix™ AAV2 (Capsid Protein VP1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-AAV5-CP | PepMix™ AAV5 (Capsid Protein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-AAV6-VP1 | PepMix™ AAV6 (Capsid protein VP1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-AAV8-CP | PepMix™ AAV8 (Capsid protein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-AAV9-VP1 | PepMix™ AAV9 (Capsid Protein VP1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-ACTL8 | PepMix™ Human (ACTL8) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-ACTS | PepMix™ Human (Actin) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 8789 | jpt | 4-6周 | 上海起發(fā) |
PM-AFP | PepMix™ Human (AFP) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-AQP4 | PepMix™ Human (Aquaporin-4) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-ASPFU-CRF1 | PepMix™ Aspergillus fumigatus (Probable glycosidase crf1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-ASPFU-GEL1 | PepMix™ Aspergillus fumigatus (Glucanosyltransferase gel1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-BKV-AGP | PepMix™ BKV (Agnoprotein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-BKV-LTA | PepMix™ BKV (large T antigen) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-BKV-STA | PepMix™ BKV (small T antigen) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-BKV-VP1 | PepMix™ BKV (capsid protein VP1) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-BKV-VP2 | PepMix™ BKV (capsid protein VP2) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-BKV-VP3 | PepMix™ BKV (capsid protein VP2, isoform VP3) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-BORR-OSPA-1 | PepMix™ Borrelia (OspA protein) Ultra | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 12138 | jpt | 4-6周 | 上海起發(fā) |
PM-BRAC | PepMix™ Human (Brachyury) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-BRAF | PepMix™ Human (BRAF) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-C1 | PepMix™ Human (HLA classI Ig-like C1 type domain) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9265 | jpt | 4-6周 | 上海起發(fā) |
PM-CAND-MP65 | PepMix™ Candida (MP65) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 9996 | jpt | 4-6周 | 上海起發(fā) |
PM-C-Brea | PepMix™ Collection Breast Cancer | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 83368 | jpt | 4-6周 | 上海起發(fā) |
PM-CCHFV-MP | PepMix™ Crimean-Congo hem. fever virus (M Polyprotein / IbAr10200) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 16932 | jpt | 4-6周 | 上海起發(fā) |
PM-CCHFV-NP | PepMix™ Crimean-Congo hem. fever virus (Nucleoprotein / IbAr10200) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10778 | jpt | 4-6周 | 上海起發(fā) |
PM-CEA | PepMix™ Human (CEA) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 11577 | jpt | 4-6周 | 上海起發(fā) |
PM-C-EBV-1 | PepMix™ Collection EBV (2x1ug/peptide) | 2xaliquotsofeachpeptidepool(1ug/peptide/pool) | 23137 | jpt | 4-6周 | 上海起發(fā) |
PM-C-EBV-2 | PepMix™ Collection EBV (25ug/peptide) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 134266 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-E-1 | CEF Pool (extended) | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 3706 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-E-2 | CEF Pool (extended) | 120nmol/peptide | 22270 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-E-4 | CEF Pool (extended) | 120nmol/peptide | 26741 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-S-1 | CEF Pool (standard) | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 3247 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-S-2 | CEF Pool (standard) | 120nmol/peptide | 19499 | jpt | 4-6周 | 上海起發(fā) |
PM-CEF-S-4 | CEF Pool (standard) | 120nmol/peptide | 23375 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFSX-1 | CEFSX Ultra SuperStim Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 12444 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFSX-2 | CEFSX Ultra SuperStim Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 14926 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-1 | CEFT Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 3247 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-2 | CEFT Pool | 120nmol/peptide | 19499 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-MHC-II-2 | CEFT MHC-II Pool | 120nmol/peptide | 17408 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-MHC-II-3 | CEFT MHC-II Pool | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 3485 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFT-MHC-II-4 | CEFT MHC-II Pool | 120nmol/peptide | 20893 | jpt | 4-6周 | 上海起發(fā) |
PM-CEFX-3 | CEFX Ultra SuperStim Pool MHC-II Subset | 15nmol(approx.25ug)/peptideforstimulationof2,5x108cells | 4420 | jpt | 4-6周 | 上海起發(fā) |
PM-CFTR | PepMix™ Human (CFTR) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 15657 | jpt | 4-6周 | 上海起發(fā) |
PM-CHADVY25-L2-1 | PepMix™ Chimpanzee Adenovirus Y25 (Penton Protein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 8636 | jpt | 4-6周 | 上海起發(fā) |
PM-CHADVY25-L3-1 | PepMix™ Chimpanzee Adenovirus Y25 (Hexon Protein) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 10013 | jpt | 4-6周 | 上海起發(fā) |
PM-C-HCMV-1 | PepMix™ Collection Human CMV (2x1ug/peptide) | 2xaliquotsofeachpeptidepool(1ug/peptide/pool) | 24106 | jpt | 4-6周 | 上海起發(fā) |
PM-C-HCMV-2 | PepMix™ Collection Human CMV (25ug/peptide) | 25ug(approx.15nmol)/peptide(forstimulationofupto2,5x108cells) | 168606 | jpt | 4-6周 | 上海起發(fā) |
(*此為部分產品價格完整價格請下載文件)
關鍵詞:jpt、多肽、PM-VZV-gE、PM-CEFX-2、PM-HPV16-E7
電話
QQ咨詢
4006551678